Tuesday 14th May 2013 |
Text too small? |
Synlait Milk, the dairy company controlled by China's Bright Dairy & Food, is considering an initial public offering in New Zealand three years after abandoning such a capital raising because of lack of investor demand.
Bright Dairy emerged with a 51 percent stake in 2010, paying $82 million and said at the time it would consider a share market listing in three to five years. Bright Dairy would be entitled to new shares to retain its holding, it said back then. Synlait Ltd, associated with the company's founders, owns the rest.
Bright Dairy gave no details about the potential size of an IPO in a statement to the Shanghai Stock Exchange, Bloomberg News reported.
A spokesman for Synlait Milk said the company will make a statement shortly.
Synlait processes more than 500 million litres of milk a year. In December it announced a maiden profit for the year to July 31, 2012, of $6.3 million.
Equity investors wary of stock offerings in the wake of the global financial crisis, which dried up credit markets. More recently, a host of new issues have been flagged as coming to market, including SLI Systems, Wynyard and Serko, a technology company.
The market has been buoyed by the float of state-owned MightyRiverPower and the prospect of another SOE coming to market later this year, while the benchmark NZX 50 Index has been charting record highs this month.
Last week, Synlait Milk said it was investing $15 million to upgrade its Special Milks Drier at Dunsandel as it looks to further tap into the $15 billion a year demand for infant formula in China.
Chief executive John Penno said the decision to invest in the high value ingredient had been stimulated by contracts with eight significant customers for infant formula including YinQiao Xi'An, the largest dairy manufacturer in north western China, Synlait Milk's cornerstone shareholder Bright Dairy and A2 Corporation which will soon launch is own a2 infant formula in China.
BusinessDesk.co.nz
No comments yet
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report